Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07282574

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

The main purpose of this study is to assess the efficacy of RO7268489 in adults with progressive multiple sclerosis (PMS) receiving ocrelizumab. After the end of the double-blind period, an open-label (OL) extension may allow eligible participants to receive open-label RO7268489.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Southern Neurology, Kogarah, New South Wales, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • PMS, in accordance with the revised 2017 McDonald criteria
  • Expanded disability status scale (EDSS) at screening between 3.0 and 6.0 inclusive

Exclusion criteria

  • MS relapse during the 6 months preceding the randomization date
  • Lack of peripheral venous access
  • History of alcohol or other drug abuse, in the opinion of the investigator, within 5 years prior to screening
  • Inability to complete an magnetic resonance imaging (MRI)
  • Contraindications to ocrelizumab mandatory pre-medications
  • Treatment with intravenous immunoglobulin (IV Ig) or plasmapheresis within 12 weeks prior to screening

Treatment and study plan

RO7268489

Drug

RO7268489 will be administered per schedule as specified in the arms.

Ocrelizumab

Drug

Ocrelizumab will be administered per schedule as specified in the arms.

Other names: RO4964913, Ocrevus

Placebo

Drug

Placebo will be administered per schedule as specified in the arms.

Primary outcomes

  1. Time From Randomization to the First Occurrence of Composite Confirmed Disability Progression (cCPD) Confirmed for at Least 12 Weeks (cCDP12)

    Time frame: Up to approximately 110 weeks

    Time from randomization to the first occurrence of cCDP12 according to at least one of the following 3 criteria:

    • 12-week confirmed disability progression (CDP12)
    • 12-week confirmed increase in Timed 25-Foot Walk Test (T25FWT) or
    • 12-week confirmed increase in 9-Hole Peg Test (9-HPT) The EDSS is a disability scale is based on a standard neurological examination that ranges in 0.5-point steps from 0 (normal) - 10 (death). T25FWT=time taken to walk 25 feet, typically measured in seconds. The longer it takes to walk, the higher score, which indicates deterioration. Lower times indicate better performance and greater mobility. In 9-HPT, participants are instructed to place pegs one by one into each of nine holes arranged in a board stabilized with a plastic nonslip sheet on a solid table, and then to remove these pegs from the holes. The shorter time it takes to complete the task indicates a better outcome.

Secondary outcomes

  1. Time From Randomization to the First Occurrence of 24-Week Confirmed ≥4-Point Decrease (Worsening) in Symbol Digit Modalities Test (SDMT)

    Time frame: Up to approximately 110 weeks

    The SDMT is a performance measure of processing speed that is widely used to assess cognitive function in response to treatment. It's brief, easy to administer, and involves a simple substitution task that healthy children and adults can easily perform. Using a reference key, the participant has 90 seconds to pair specific numbers with given geometric figures. The total SDMT score is the total number of correct responses and ranges from 0 to 110, with a higher score indicating a higher level of processing speed. A four-point change from baseline is typically considered clinically meaningful.

  2. Change From Baseline in Total Brain Volume

    Time frame: Up to approximately 110 weeks

  3. Time to Onset of 24-Week cCDP (cCDP24)

    Time frame: Up to approximately 110 weeks

  4. Time to Onset of 12-Week Confirmed Disability Progression CDP (CDP12)

    Time frame: Up to approximately 110 weeks

  5. Time to Onset of 24-Week CDP (CDP24)

    Time frame: Up to approximately 110 weeks

  6. Time to ≥ 20% Increase in 12-week Confirmed Timed 25-Foot Walk Test (T25FWT)

    Time frame: Up to approximately 110 weeks

    The time taken to walk 25 feet, typically measured in seconds. The longer it takes to walk, higher the score, which indicates deterioration and greater impairment. Lower times indicate better performance and greater mobility. Lower the mean change in the score over time, the better performance.

  7. Time to ≥ 20% Increase in 24-week Confirmed T25FWT

    Time frame: Up to approximately 110 weeks

    The time taken to walk 25 feet, typically measured in seconds. The longer it takes to walk, higher the score, which indicates deterioration and greater impairment. Lower times indicate better performance and greater mobility. Lower the mean change in the score over time, the better performance.

  8. Time to ≥ 20% Increase in 12-week Confirmed 9-Hole Peg Test (9-HPT)

    Time frame: Up to approximately 110 weeks

    Participants are instructed to place pegs one by one into each of nine holes arranged in a board stabilized with a plastic nonslip sheet on a solid table, and then to remove these pegs from the holes. Both the dominant and non-dominant hands are tested twice (two consecutive trials for each hand). The participants are required to complete two successful trials for each hand. The amount of time (in seconds) required to place and remove all nine pegs is recorded for each trial. More time = higher raw scores, which indicates deterioration. The lower mean change in the score over time, the better the performance.

  9. Time to ≥ 20% Increase in 24-week Confirmed 9-HPT

    Time frame: Up to approximately 110 weeks

    Participants are instructed to place pegs one by one into each of nine holes arranged in a board stabilized with a plastic nonslip sheet on a solid table, and then to remove these pegs from the holes. Both the dominant and non-dominant hands are tested twice (two consecutive trials for each hand). The participants are required to complete two successful trials for each hand. The amount of time (in seconds) required to place and remove all nine pegs is recorded for each trial. More time = higher raw scores, which indicates deterioration. The lower mean change in the score over time, the better the performance.

  10. Plasma 2-arachidonoylglycerol (2-AG) Levels

    Time frame: Up to approximately 110 weeks

  11. Change From Baseline in Plasma 2-AG Levels

    Time frame: Up to approximately 110 weeks

  12. Number of Participants With Adverse events (AEs)

    Time frame: Up to 5 years

  13. Number of Participants With Treatment Discontinuations due to AEs

    Time frame: Up to 5 years

  14. Proportion of Participants With Suicidal Ideation or Behavior, as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to 5 years

    C-SSRS is an assessment tool used to assess lifetime suicidality of participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, and attempts with actual/potential lethality. Categories have binary responses (yes/no) and include Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation/behavior is indicated by a "yes" answer to any of the listed categories. Score of 0 is assigned if no suicide risk is present. Score of 1 or higher indicate suicidal ideation or behavior.

  15. Plasma Concentrations of RO7268489 and Its Metabolite(s)

    Time frame: Up to 5 years

Study contacts

Contact information is provided by the study sponsor or research team.

Fastest response: use the inquiry form. No email attachments. https://www.gene.com/contact-us/submit-medical-inquiry

CONTACT

Reference Study ID Number: BP46016 https://forpatients.roche.com/

CONTACT

[email protected]

888-662-6728 (U.S. Only)

Sponsors and collaborators

Lead sponsor

Hoffmann-La Roche

Industry

Registry information

Official study title

A Multi-center, Double-blind, Placebo-controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, a Monoacylglycerol Lipase Inhibitor, as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis

Acronym: Mintaka

Important dates

Study start
2026
Primary completion
2028
Study completion
2030
First posted
Dec 15, 2025
Registry last updated
Jul 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.